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Abstract
Background: Substantial evidence from human post-mortem and genetic studies has linked the neurotrophic
factor neuregulin 1 (NRG1) to the pathophysiology of schizophrenia. Genetic animal models and in vitro
experiments have suggested that altered NRG1 signaling, rather than protein changes, contributes to the
symptomatology of schizophrenia. However, little is known about the effect of NRG1 on schizophrenia-
relevant behavior and neurotransmission (particularly GABAergic and glutamatergic) in adult animals.
Method: To address this question, we treated adult mice with the extracellular signaling domain of NRG1 and
assessed spontaneous locomotor activity and acoustic startle response, as well as extracellular GABA,
glutamate, and glycine levels in the prefrontal cortex and hippocampus via microdialysis. Furthermore, we
asked whether the effect of NRG1 would differ under schizophrenia-relevant impairments in mice and
therefore co-treated mice with NRG1 and phencyclidine (PCP) (3mg/kg). Results: Acute intraventricularly-
or systemically-injected NRG1 did not affect spontaneous behavior, but prevented PCP induced
hyperlocomotion and deficits of prepulse inhibition. NRG1 retrodialysis (10nM) reduced extracellular
glutamate and glycine levels in the prefrontal cortex and hippocampus, and prevented PCP-induced increase
in extracellular GABA levels in the hippocampus. Conclusion: With these results, we provide the first
compelling in vivo evidence for the involvement of NRG1 signaling in schizophrenia-relevant behavior and
neurotransmission in the adult nervous system, which highlight its treatment potential. Furthermore, the
ability of NRG1 treatment to alter GABA, glutamate, and glycine levels in the presence of PCP also suggests
that NRG1 signaling has the potential to alter disrupted neurotransmission in patients with schizophrenia.
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Abstract
Background: Substantial evidence from human post-mortem and genetic studies has linked the neurotrophic factor 
neuregulin 1 (NRG1) to the pathophysiology of schizophrenia. Genetic animal models and in vitro experiments have suggested 
that altered NRG1 signaling, rather than protein changes, contributes to the symptomatology of schizophrenia. However, little 
is known about the effect of NRG1 on schizophrenia-relevant behavior and neurotransmission (particularly GABAergic and 
glutamatergic) in adult animals.
Method: To address this question, we treated adult mice with the extracellular signaling domain of NRG1 and assessed 
spontaneous locomotor activity and acoustic startle response, as well as extracellular GABA, glutamate, and glycine levels in 
the prefrontal cortex and hippocampus via microdialysis. Furthermore, we asked whether the effect of NRG1 would differ under 
schizophrenia-relevant impairments in mice and therefore co-treated mice with NRG1 and phencyclidine (PCP) (3 mg/kg).
Results: Acute intraventricularly- or systemically-injected NRG1 did not affect spontaneous behavior, but prevented PCP 
induced hyperlocomotion and deficits of prepulse inhibition. NRG1 retrodialysis (10 nM) reduced extracellular glutamate and 
glycine levels in the prefrontal cortex and hippocampus, and prevented PCP-induced increase in extracellular GABA levels in 
the hippocampus.
Conclusion: With these results, we provide the first compelling in vivo evidence for the involvement of NRG1 signaling 
in schizophrenia-relevant behavior and neurotransmission in the adult nervous system, which highlight its treatment 
potential. Furthermore, the ability of NRG1 treatment to alter GABA, glutamate, and glycine levels in the presence 
of PCP also suggests that NRG1 signaling has the potential to alter disrupted neurotransmission in patients with 
schizophrenia.
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Introduction
Substantial evidence from human and animal studies has linked 
the neurotrophic factor neuregulin 1 (NRG1) to the pathophysi-
ology of schizophrenia (Stefansson et al., 2002; Petryshen et al., 
2005; Buonanno, 2010; Agim et al., 2013). The majority of identi-
fied polymorphisms are located in the non-coding region of the 
NRG1 gene. This suggests a change in NRG1 isoform expression 
levels, rather than a change in the amino acid sequence of the 
proteins themselves (Buonanno, 2010). Post-mortem analyses 
of NRG1 mRNA and protein expression levels in the prefron-
tal cortex (PFC) and hippocampus have reported increased, 
decreased, and unchanged levels of NRG1 isoforms and altered 
isoform type ratios in patients with schizophrenia (Hashimoto 
et  al., 2004; Hahn et  al., 2006; Law et  al., 2006; Bertram et  al., 
2007; Chong et al., 2008; Barakat et al., 2010). While differences 
in NRG1 expression vary between patients, the findings suggest 
altered NRG1 signaling in the schizophrenia pathophysiology.
Genetic animal models with previously identified or novel 
mutations in the NRG1 gene have been developed (Lu et al., 2011). 
These modifications resulted in schizophrenia-relevant behavio-
ral (e.g. hyperlocomotion and sensorimotor gating impairments) 
and neurochemical (e.g. altered glutamate and γ-aminobutyric 
acid [GABA] neurotransmission) impairments (Stefansson et al., 
2002; Karl et al., 2007; Kato et al., 2010; Wen et al., 2010; Shamir 
et al., 2012; Luo et al., 2013; Mitchell et al., 2013; Yin et al., 2013). 
Furthermore, differences in brain NRG1 expression have been 
identified in several schizophrenia-relevant rodent models (Du 
Bois et al., 2012; Radonjić et al., 2013; Rhein et al., 2013; Swerdlow 
et al., 2013). The rodent studies indicate that changes to NRG1 
signaling have functional consequences relevant to the schizo-
phrenia pathophysiology.
The neurotrophic factor NRG1 is expressed throughout the 
nervous system, with expression levels strongly influenced by 
neuronal activity (Liu et al., 2011). Recent research has identified 
an involvement of NRG1 signaling in neurotransmission of the 
adult brain, such as GABA release (Woo et al., 2007; Wen et al., 
2010), GABA receptor currents (Woo et al., 2007; Chen et al., 2010), 
and receptor expression levels (Okada and Corfas, 2004; Allison 
et al., 2011; Mitchell et al., 2013). Furthermore, glutamate release 
(Gu et al., 2005; Pitcher et al., 2011; Yin et al., 2013) and N-Methyl-
D-aspartic acid (NMDA) receptor functions are also reportedly 
influenced by NRG1 signaling (Gu et al., 2005; Bjarnadottir et al., 
2007; Bennett, 2009; Pitcher et al., 2011). The neurotransmission 
effects of NRG1 appear to be primarily mediated through the epi-
dermal growth factor receptor tyrosine kinase ERBB4, but might 
also involve other epidermal growth factor receptor tyrosine 
kinase (ERBB) receptor isoforms (Iwakura and Nawa, 2013; Mei 
and Nave, 2014). ERBB4 is expressed on GABAergic interneu-
rons and glia in the PFC and hippocampus (Gerecke et al., 2001; 
Longart et al., 2007; Calvo et al., 2010; Fazzari et al., 2010; Neddens 
et  al., 2011), with other ERBB isoforms expressed through-
out the central and peripheral nervous system (Iwakura and 
Nawa, 2013). The in vitro studies suggest that NRG1 signaling is 
involved in neurotransmission relevant to schizophrenia patho-
physiology, potentially contributing to differences observed in 
the GABAergic and glutamatergic neurotransmitter systems in 
patients (Moghaddam and Javitt, 2012; Inan et al., 2013). However, 
the consequence of altered NRG1 signaling on schizophrenia-rel-
evant neurotransmission differences has not yet been explored.
Genetic animal models and in vitro studies indicate a role for 
NRG1 signaling in schizophrenia, but how NRG1 affects schizo-
phrenia-relevant behavior and neurotransmission (particularly 
GABAergic and glutamatergic) in adult animals is unknown. 
To address this question, we treated adult mice with the 
extracellular signaling domain of NRG1 and assessed spontane-
ous behavior (locomotor activity and acoustic startle response), 
as well as extracellular neurotransmitter levels (GABA, gluta-
mate, and glycine). Furthermore, we asked whether the effect of 
NRG1 would differ under schizophrenia-relevant impairments 
in mice, since differences in NRG1 expression levels have been 
found in patients with schizophrenia. We therefore co-treated 
mice with NRG1 and phencyclidine (PCP), a commonly used sub-
stance for modeling schizophrenia-like behavioral and neuro-
transmission impairments in rodents (Adell et  al., 2012; Javitt 
et  al., 2012; Moghaddam and Krystal, 2012; Pratt et  al., 2012). 
With our experiments we show that NRG1 treatment prevented 




Ten-week-old male C57BL6j mice were purchased from Animal 
Resource Centre for locomotor activity and microdialysis 
experiments and Australian BioResources for sensorimotor 
gating experiments. Animals were group-housed in open-lid 
cages with minimal enrichment (M1 polypropylene cages; Able 
Scientific) and maintained on a 12 h light/dark cycle (light on 
at 0600 hours) with food and water available ad libitum in the 
animal facilities of the University of Wollongong (open field 
and microdialysis experiments) and Neuroscience Research 
Australia (sensorimotor gating experiments). All research and 
animal care procedures were approved by either the Animal 
Ethics Committee of the University of Wollongong (AE10/07 and 
AE11/18) or University of New South Wales (4149794) and were 
in agreement with the Australian Code of Practice for the Care 
and Use of Animals for Scientific Purposes. Mice were acclima-
tized for at least one week prior to experiments. For behavioral 
studies, testing order was pseudo-randomized to account for 
diurnal variations. For microdialysis studies, testing order was 
constant to allow the comparison of molecular responses.
Drugs
All compounds were obtained from Sigma except where speci-
fied otherwise. Drugs were freshly prepared on each treatment 
day. Recombinant human NRG1 (NRG1-β1/HRG1-β1 EGF domain 
CF; R&D Systems) and PCP were dissolved in either artificial cer-
ebrospinal fluid (ACSF, 119 mM NaCl; 2.5 mM CaCl2; 2.5 mM KCl; 
1.3 mM MgSO4; 1 mM NaH2PO4; 26.2 mM NaHCO3; 11 mM glucose, 
7.4 pH, 290 mOsm/kg) for i.c.v. injections and retrodialysis or 
in 0.9% NaCl (vehicle) for i.p. injections. For behavioral testing, 
each mouse received no more than three treatments with an 
inter-test interval of one week.
Open Field Behavior
The receptors for NRG1 are expressed throughout the nerv-
ous system and have also been found on muscle tissue (Zhu 
et  al., 1995; Bersell et  al., 2009; Wadugu and Kühn, 2012). 
Peripheral NRG1 treatment might therefore directly affect mus-
cle cells, masking possible central nervous system responses. 
Independent open field experiments with i.c.v. and i.p. NRG1 
administration were therefore performed.
Intracerebroventricular Cannula Implantation
Mice destined for i.c.v. treatment underwent surgical implan-
tation of an i.c.v. cannula one week prior to experiments. 
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Animals were anaesthetized with an inhalation 1.5% isoflurane 
(Delvet)/98.5% oxygen mix. Using a stereotactic frame (Kopf 
Instruments), a 21 G guide cannula was implanted into the brain, 
targeting the right lateral ventricle (Bregma -0.25 mm rostral, 
-1 mm medial, -1.5 mm from top of skull; Paxinos and Franklin, 
2001). The guide cannula was fixed to the skull with anchor 
screws (2 mm, Microbiotech) and dental acrylic (Ketac Cem, 
Halas Dental Limited). All animals were injected with 0.1 ml of a 
depot-antibiotic substance (Medicam, Boehriner Ingelheim) and 
additionally received it in their drinking water (0.1%) for three 
days following surgery. Dummy cannula (28 G), were inserted 
into the guide to keep it clean and prevent occlusion. Following 
surgery, mice were individually housed and their recovery was 
monitored daily until the behavioral experiments commenced.
Locomotion After Treatment
Mice were habituated to a round open field arena (40 cm diameter) 
for 30 min before i.p. and/or i.c.v. injections, and re-exposed to the 
open field for 30 min thereafter. For the i.p. experiments, all ani-
mals (n = 8/group) received an i.p. injection of NRG1 (5, 25, or 50 µg/
kg), PCP (3 mg/kg), PCP + NRG1 (5, 25, or 50 µg/kg), or vehicle. For 
the i.c.v. experiments, all animals (n = 6–8/group) received an i.c.v. 
injection of NRG1 (3, 30, or 300 ng/kg) or ACSF and simultaneously 
an i.p. injection of PCP (3 mg/kg) or vehicle. NRG1 concentrations 
were selected below reported sedative levels (Snodgrass-Belt et al., 
2005). Distance traveled was recorded before and after injections 
using the EthoVision tracking system (Noldus). Activity data were 
collected in 5 min intervals, with individual post-treatment dis-
tance traveled normalized to the habituation performance.
Sensorimotor Gating
Sensorimotor gating (i.e. pre-pulse inhibition of startle response) 
was assessed as previously published (Karl et al., 2011). Briefly, 
one week before testing, mice (n = 8/group) were allowed 30 min 
habituation to the prepulse inhibition (PPI) chambers at back-
ground noise levels (70 dB; SR-LAB; San Diego Instruments). 
Animals received an i.p. injection of NRG1 (5, 25, or 50 µg/kg), 
PCP (3 mg/kg), PCP + NRG1 (5, 25, or 50 µg/kg), or vehicle directly 
following a 5 min re-acclimatization period in the PPI chambers. 
Sensorimotor gating was tested in 100 trials over 25 min, con-
sisting of 3 startle response blocks and PPI response trails (pre-
pulse intensities: 74 dB, 82 dB, and 86 dB),
Microdialysis and Amino Acid Quantification
Microdialysis was performed as described previously (Landgraf 
et  al., 2003). Briefly, similar to the i.c.v. cannula implantation, a 
microdialysis guide cannula (MAB 6.14.IC Microbiotech/SE) was 
surgically implanted into either the medial PFC or dorsal CA1 
to accommodate a microdialysis probe. Mice were individually 
housed in purpose-built microdialysis cages (25 x 25 x 40 cm, 
grey Polyvinyl chloride (PVC) with clear front) for all experimen-
tal procedures, which allowed free access to food and water. After 
seven days of recovery, the microdialysis probe (1 mm membrane 
length, 15 kDa cut off, MAB 6.14.1, Microbiotech) was inserted into 
the guide cannula and lowered into the respective target area 
of the right mPFC/dCA1 2.5 h before the first treatment. It was 
connected via low volume in- and outflow tubing (FEP-tubing, 
4001004, Microbiotech; fluid swivel 375/D/22QM, Instechlabs) via a 
counter-balanced lever arm to a syringe pump (1 µl/min, Harvard 
Instruments). Microdialysis samples were collected in 10 min 
intervals 2.5 h after probe insertion. Animals received 10 min infu-
sions with NRG1 (10 nM), PCP (10 µM), and NRG1 + PCP, separated 
by 2.5 h of ACSF each. Potassium-stimulated neurotransmitter 
release (Stanford et  al., 2000) and probe placement were con-
firmed before data analysis.
Gas Chromatography Mass Spectrometry Sample 
Processing and Analysis
Derivatization followed a previously published method (Eckstein 
et al., 2008). Briefly, samples were supplemented with heavy iso-
topes (20 pmole GABA-d6, 200 pmole Glycine-C13-2, N15, 2 pmole 
Glutamate-d5) and diluted in acetonitrile/methanol (1:1) before 
centrifugation. The supernatant was dried off at 37°C under 
nitrogen before derivatization with pentafluoropropionic acetic 
anhydride and 2,2,3,3,3-pentafluoro-1-propanol (PM Separations 
PTY). Following derivatization, samples were resuspended in tol-
uene for analysis. Samples were analyzed using negative chemi-
cal ionization in a gas chromatograph with triple quad mass 
spectrometry (GC-MS/MS, 7000B & 7890A, Agilent Technologies). 
Specific multiple-reaction monitoring transitions were per-
formed to monitor the glutamate ion transition m/z 379.0  → 
m/z 188.0, qualifier transitions (m/z 537.0 → m/z 313.0 and m/z 
537.0 → m/z 217.0), and m/z 542 → m/z 221 for the correspond-
ing isotopic d5 labeled internal standard. GABA ion transition was 
detected at m/z 191.1 → 109.0, qualifier transitions (m/z 321.0 → 
m/z 301.0 and m/z 341.0 → m/z 208.0), and m/z 327 → m/z 306 for 
the corresponding isotopic d6 labeled internal standard. Glycine 
ion transition was detected at m/z 333.0 → m/z 313.0, qualifier 
transitions at m/z 333.0 → 200.0 and m/z 365.0 → 232.0, and m/z 
336.0 → m/z 316.0 for the corresponding isotopic C13-2 labeled 
internal standard. The area under the curve for peaks of GABA, 
glutamate, and glycine were normalized by their respective inter-
nal standard peaks, followed by normalization to the relevant 
baseline samples.
Statistical Analysis
Pre- and post-injection locomotor activity and startle following 
pulse-only trails were assessed by a one-way analysis of vari-
ance (ANOVA), followed by a Bonferroni’s multiple comparison 
post hoc analysis when required. Single time point differences in 
distance traveled were assessed by one-way ANOVA for repeated 
measurements, followed by Bonferroni’s multiple comparison 
post hoc analysis. Differences in PPI were assessed using two-
way repeated-measures ANOVA (treatment x pre-pulse intensity), 
followed by Bonferroni’s multiple comparison post hoc analysis. 
Treatment effects on neurotransmitter levels were assessed 
using Linear Mixed Model (LMM) on repeated measurements for 
each brain area and transmitter following baseline normaliza-
tion. Overall differences in extracellular neurotransmitter levels 
were assessed by calculating the area under the curve (AUC) for 
the entire sampling period using the trapezoidal rule. AUC and 
single time point differences were assessed by one-way ANOVA 
for repeated measurements, followed by Tukey’s post hoc analy-
sis where appropriate. Analyses were performed using SPSS 19.0 
(IBM). Statistical significance was accepted at p < 0.05 and data are 
presented as the mean ± standard error of the mean.
Results
NRG1 Treatment Does Not Alter Locomotor Activity, 
But Prevents PCP-Induced Hyperlocomotion
Increased spontaneous locomotor activity in the open field 
arena is considered to be an indirect measure of hyperdopamin-
ergic and hypoglutamateric tone experienced by patients with 
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schizophrenia during a psychotic episode (Adell et al., 2012) and 
reported from several NRG1 genetic animal models (Lu et al., 2011).
Locomotor activity differed significantly between treatment 
groups (F7, 54 = 7.35, p < 0.001), with activity of i.p. NRG1-treated 
mice being similar to vehicle-treated mice (5  µg/kg: p  =  0.22, 
25 µg/kg and 50 µg/kg: p = 0.99 vs vehicle; Figure 1A). Mice treated 
with PCP showed an increase in locomotor activity (p = 0.003 vs 
vehicle; Figure  1A), consistent with previous studies (Gleason 
and Shannon, 1997; Mouri et al., 2011). Combining PCP with NRG1 
i.p. altered the PCP-induced increase in locomotor activity in a 
concentration-dependent manner. NRG1 at 25 μg/kg, but not at 5 
or 50 µg/kg, prevented the PCP hyperlocomotive effect (p = 0.02 vs 
PCP, 5 μg/kg: p = 0.99, 50 μg/kg: p = 0.79 vs PCP; Figure 1A).
One-way ANOVA also revealed a significant treatment effect 
on locomotor activity of i.c.v. treated mice (F6, 43 = 6.6, p < 0.001). 
Locomotor activity following i.c.v. NRG1 treatment was similar 
to vehicle-treated animals (p = 0.99 for 30 ng/kg and 300 ng/kg 
vs vehicle; Figure 1B). PCP treatment again increased locomotor 
activity (p < 0.001 vs vehicle; Figure 1B). Similar to i.p. treatment, 
NRG1 i.c.v. altered the PCP effect in a concentration-dependent 
manner. NRG1 at 30 ng/kg, but not at 3 or 300 ng/kg, prevented 
PCP-induced hyperlocomotion (p  =  0.024 vs PCP; 3 ng/kg and 
300 ng/kg: p = 0.99 vs PCP; Figure 1B).
Comparing the distance traveled for each post-treat-
ment interval via repeated-measure two-way ANOVA (i.p. 
NRG1 Treatment F3, 28 = 2.93, p = 0.05; i.c.v. NRG1 Treatment F3, 
28 = 8.88, p < 0.001) showed that PCP treatment triggered hyper-
locomotion within 10 min post-treatment (p = 0.002 vs vehicle, 
Figure 1C and D). Combined treatment with either i.p. 25 μg/kg 
NRG1 (Figure  1C) or i.c.v. 30 ng/kg NRG1 (Figure  1D) prevented 
the increase in locomotor activity from the treatment onset 
(Figure 1C and D), while NRG1 treatment in the absence of PCP 
did not alter locomotor activity.
NRG1 Treatment Prevents PCP-Induced Deficit of 
Pre-Pulse Inhibition of Startle
Patients with schizophrenia show impaired sensorimotor gat-
ing (Braff et al., 2001), which can be tested in rodents through 
inhibition of startle response experiments (Geyer et  al., 2001). 
In our sensorimotor gating experiment, startle response to 
a 120 dB pulse was not affected by any of the treatments (F7, 
58 = 1.5, p = 0.18; Figure 2A). Pre-pulse intensity had a significant 
effect on PPI for vehicle-treated animals (F1.2, 8.5 = 69.52, p < 0.001; 
Figure 2B). Furthermore, PPI differed significantly between treat-
ment groups (F6, 45 = 5.55, p < 0.001). NRG1 treatment at 25 μg/kg 
and 50 μg/kg had no effect on PPI performance (p > 0.8 vs vehi-
cle), while 5 µg/kg NRG1 impaired the PPI effect at 74 and 82 dB 
pre-pulse intensity (p = 0.01 and p = 0.03 vs vehicle, respectively; 
Figure  2B). PCP treatment impaired PPI for all three pre-pulse 
intensities (74 dB: p = 0.01, 82 dB: p < 0.001, and 86 dB: p = 0.002 
vs vehicle; Figure 2B), which is consistent with previous studies 
(Bakshi and Geyer, 1995; Yee et  al., 2004). NRG1 prevented the 
PCP-induced disruption of PPI for pre-pulses of 82 and 86 dB in 
a dose-dependent manner (25 µg/kg NRG1 at 82 dB: p = 0.006; 
at 86 dB: p = 0.04; 50 µg/kg NRG1 at 82 dB: p = 0.02; Figure 2B). 
The ability of NRG1 to prevent PCP-induced sensorimotor gat-
ing impairment indicates an acute influence over several schiz-
ophrenia-relevant neurotransmitter systems.
NRG1 Reduces Glutamate and Glycine Levels in the 
Mouse PFC In Vivo
The microdialysis experiment was designed to assess the 
consequence of increased NRG1 signaling on schizophrenia-
relevant neurotransmission under healthy and impaired condi-
tions. We first measured GABA, glutamate, and glycine levels in 
Figure 1. Peripheral and central administered neuregulin 1 (NRG1) prevents PCP-induced hyperlocomotion in mice. (A & B) Post-treatment distance moved as percent-
age of habituation locomotion for varying doses of i.p. NRG1 (A, µg/kg) or i.c.v. NRG1 (B, ng/kg), administered in combination with PCP (3 mg/kg) or vehicle (A, 0.9% NaCl; 
B, artificial cerebrospinal fluid + 0.9% NaCl). Data is presented as mean percentage difference to habituation locomotion + standard error of the mean (n = 8/group). (C & 
D) Mean distance moved within 5 min windows pre- and post-treatment ± standard error of the mean (n = 8/group) after (C, i.p.) vehicle, NRG1 (25 μg/kg), PCP, or NRG1 
+ PCP (25 μg/kg + 3 mg/kg); (D, i.c.v. + i.p.) vehicle, NRG1 (30 ng/kg + 0.9% NaCl), PCP (artificial cerebrospinal fluid + 3 mg/kg), or NRG1 + PCP (30 ng/kg + 3 mg/kg). *p < 0.05, 
**p < 0.01 vs PCP; #p < 0.01, ##p < 0.001, ###p < 0.0001 vs vehicle.
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the PFC following NRG1 retrodialysis and combined with PCP. 
The retrodialysis treatments had a significant overall effect on 
extracellular glutamate and glycine levels (LMM: glutamate: 
F3, 145.8 = 11.41, p < 0.001; glycine: F3, 145.1 = 6.85, p < 0.001), with-
out affecting overall GABA levels (GABA: F3, 123.9 = 0.55, p = 0.64). 
By comparing single time point GABA levels, we identified an 
increase 10 min after NRG1 treatment (194.0 ± 47.0% of baseline, 
p  =  0.03; Figure  3A), which returned to baseline levels for the 
remaining sampling period. PCP infusion reduced extracellu-
lar GABA levels 20 min after treatment (37.6 ± 8.0% of baseline, 
p  =  0.005; Figure  3A). Combined infusion of NRG1 + PCP pre-
vented this reduction of extracellular GABA levels (104.2 ± 45%, 
p > 0.99 vs baseline; Figure 3A). GABA levels expressed as AUC 
revealed that none of the three treatments affected overall 
GABA concentration across the sampling period (F3, 18.6  =  0.9, 
p = 0.46; Figure 3B).
NRG1 infusion reduced extracellular glutamate levels in the 
PFC throughout the sampling period (LMM: 50.8 ± 10.2% of base-
line, p < 0.001; AUC: 52.2 ± 9.8% of baseline, p = 0.005; Figure 3C 
and D). However, neither PCP nor NRG1 + PCP affected glutamate 
levels at single time points or during the entire sampling period 
(LMM: p = 0.69 and p > 0.99 vs baseline, AUC: p = 0.81 and p = 0.65 
vs baseline, respectively; Figure 3C and D). Overall, extracellu-
lar glycine levels were reduced following NRG1 infusion (AUC: 
57.5 ± 9.8% of baseline, p = 0.008; Figure 3E and F). Glycine levels 
were not affected by PCP (AUC: p = 0.98 vs baseline). Combined 
NRG1 + PCP treatment led to a marked increase in glycine lev-
els during the infusion period (219.0 ± 61.0% of baseline, p = 0.02; 
Figure 3E). This increase did not persist for the remaining sam-
pling period (AUC: 125.1 ± 10.4% of baseline, p  = 0.11). The PFC 
microdialysis experiment shows that NRG1 has an immediate 
influence on extracellular neurotransmitter levels with poten-
tial relevance to schizophrenia.
Figure  2. Peripheral neuregulin 1 (NRG1) injection prevents PCP-induced pre-
pulse inhibition (PPI) impairment. Mice (n = 7–8/group) treated intraperitoneally 
with vehicle, NRG1 (5, 25, or 50 μg/kg), PCP (3 mg/kg), or NRG1 + PCP (5, 25, or 
50 μg/kg NRG1 + 3 mg/kg PCP). (A) Treatments had no effect on startle response 
to 120 dB pulses (one-way analysis of variance, F7, 58 = 1.502, p = 0.18). Values are 
presented as mean of startle intensity + standard error of the mean. (B) Treat-
ment effect on PPI following different prepulse intensities. Values are presented 
as mean percentage of PPI + standard error of the mean. #p < 0.05, ##p < 0.01, 
###p < 0.001 vs vehicle (veh); *p < 0.05, **p < 0.01 vs PCP.
Figure  3. Neuregulin 1 (NRG1) reduces extracellular glutamate and glycine in 
the prefrontal cortex (PFC) in vivo. Mice (n  =  8–10/treatment) received a local 
infusion of NRG1 (10 nM), PCP (10 µM), or NRG1 + PCP for 10 min in the PFC by 
retrodialysis. Extracellular GABA (A & B), glutamate (C & D), and glycine (E & F) 
levels are expressed as a percentage of the respective mean baseline value ± 
standard error of the mean for each time point (A, C, E) or baseline equivalent 
for area under the curve analysis (B, D, F). Dotted lines indicate baseline levels 
before each treatment. *p < 0.05 NRG1 + PCP vs baseline; #p < 0.05 PCP vs baseline; 
+p < 0.05, ++p < 0.01 NRG1 vs baseline.
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NRG1 Reduces Glutamate and Glycine Levels 
and Prevents PCP-Induced GABA Increase in the 
Hippocampus In Vivo
Impaired signaling between the hippocampus and PFC has been 
implicated in the pathophysiology of schizophrenia (Godsil 
et al., 2013). We therefore further investigated the effect of NRG1 
increase on hippocampal neurotransmitter levels. In the dor-
sal CA1 of the hippocampus, the retrodialysis treatments had a 
significant effect on overall extracellular glutamate and glycine 
levels (glutamate: F3, 158.9 = 16.85, p < 0.001; glycine: F3, 159.1 = 6.68, 
p < 0.001), but only affected GABA levels at single time points 
(F3, 147.4 = 1.39, p = 0.248). NRG1 showed a tendency to increase 
GABA levels during the infusion period (212.0 ± 66.0% of baseline, 
p  =  0.1), with post-infusion samples remaining close to base-
line (Figure 4A). PCP significantly increased extracellular GABA 
concentration during the 10 min infusion period (313.0 ± 82.8% 
of baseline, p = 0.01; Figure 4A). Co-infusion of NRG1 prevented 
the PCP effect (103.0 ± 16.0% of baseline, p = 0.96; Figure 4A). AUC 
analysis showed a trend in overall treatment effect on GABA lev-
els (F3,19.9 = 2.8, p = 0.07), with a trend towards reduced overall 
GABA levels following NRG1 + PCP (NRG1: p = 0.31; PCP: p > 0.99; 
NRG1 + PCP: p = 0.07 vs baseline; Figure 4B).
Glutamate levels were reduced 10 min after NRG1 treatment 
for 20 min (10 min: 54.9 ± 8.9% of baseline, p  =  0.006; 20 min: 
61.7 ± 7.9%, p  <  0.007; 30 min: 37.7 ± 4.3%, p  <  0.001; Figure  4C). 
PCP increased extracellular glutamate levels 20 min after treat-
ment (135.3 ± 10.8% of baseline, p = 0.06; Figure 4C). Combined 
treatment of NRG1 + PCP reduced glutamate levels during the 
infusion period (28.0 ± 9.0% of baseline, p  <  0.001), with lev-
els remaining below baseline until 50 min after treatment 
(Figure  4C). The combined treatment therefore prevented the 
20 min PCP peak (70.0 ± 10.2% of baseline, p < 0.001 vs PCP). The 
AUC analysis (F 3, 23.2 = 5.92, p = 0.004) confirmed this observation, 
with NRG1 and NRG1 + PCP leading to glutamate levels below 
baseline values (64.3 ± 9.2%, p = 0.07 and 53.2 ± 12.6%, p = 0.01 vs 
baseline, respectively; Figure 4D).
Hippocampal glycine levels were unaffected by NRG1 infu-
sion throughout the sampling period (LMM: p = 0.17; Figure 4E). 
PCP infusion caused an increase in extracellular glycine lev-
els 50 min after treatment (186.5 ± 47.0% of baseline, p  <  0.05; 
Figure 4E). However, combined infusion of NRG1 + PCP increased 
glycine levels during the infusion period (196.0 ± 58.0% of base-
line, p = 0.047, Figure 4E). None of the treatments affected overall 
glycine levels compared to baseline (Figure 4F).
Discussion
In the present study, we showed that NRG1 treatment: (1) did not 
affect spontaneous behavior, but prevented PCP-induced behav-
ioral impairments in the open field and prepulse inhibition par-
adigms; (2) reduced extracellular glutamate and glycine levels 
in the PFC and hippocampus; and (3) prevented PCP-induced 
changes to extracellular GABA levels in the hippocampus. With 
these results we provide the first compelling in vivo evidence for 
the involvement of NRG1 in schizophrenia-relevant behavior 
and neurotransmission and its treatment potential.
NRG1 Treatment Does Not Affect Spontaneous 
Behavior, But Prevents PCP-Induced Impairments
NRG1 administration did not adversely affect performance 
in the behavioral paradigms tested. Mice receiving central 
or peripheral NRG1 injections traveled a similar distance as 
vehicle-treated mice, and no difference in spontaneous behav-
ior was observed. This finding is in line with a published study 
which reports no difference in locomotor activity 24 h and 
28 d after two days of subcutaneous NRG1 (166 µg/kg) treatment 
in mice (Mahar et al., 2011). Experiments with genetic animals 
have shown that reduced NRG1 (e.g. reducing ERBB or NRG1 
expression) or increased NRG1 signaling (e.g. overexpression of 
NRG1 type I) leads to hyperactivity in the open field arena (Karl 
et al., 2007; Kato et al., 2010; Wen et al., 2010; Luo et al., 2013; 
Yin et al., 2013). While acute application of NRG1 had no effect 
on locomotion, chronically altering the NRG1 signaling pathway 
likely caused the locomotor differences in genetically-modified 
Figure  4. Neuregulin 1 (NRG1) prevents PCP-induced increase in GABA levels 
and reduces extracellular glutamate in the presence of PCP in the dorsal hip-
pocampus CA1 (dCA1) in vivo. Mice (n = 8–10/treatment) received a local infusion 
of NRG1 (10 nM), PCP (10 µM), or NRG1 + PCP for 10 min in the dCA1 by retrodialy-
sis. Extracellular GABA (A & B), glutamate (C & D), and glycine (E & F) levels are 
expressed as a percentage of the respective mean baseline value ± standard error 
of the mean for each time point (A, C, E) or baseline equivalent for area under the 
curve analysis (B, D, F). Dotted lines indicate baseline levels before each treat-
ment. T*p = 0.07, *p < 0.05, **p < 0.001 NRG1 + PCP vs baseline; T#p = 0.06,  #p < 0.05, 
##p < 0.01 PCP vs baseline; T+p = 0.07, +p < 0.05, ++p < 0.001 NRG1 vs baseline.
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animals, instead of short-term effects of NRG1 on related 
neurotransmission.
Several NRG1 transgenic animal models show sensorimotor 
gating impairments (Chen et al., 2008; Deakin et al., 2009; Wen 
et al., 2010; Karl et al., 2011). We therefore assessed the acoustic 
startle response following NRG1 treatment in wild type mice. 
Neither startle response nor PPI performance was affected by 
25 or 50 μg/kg NRG1 compared to vehicle, while 5 μg/kg reduced 
the PPI effect. These results suggest that sensorimotor gating 
differences caused by genetically modifying the NRG1 signaling 
pathway are not related to acute NRG1 signaling. Furthermore, 
the dose-dependent behavioral response indicates that minor 
imbalances in NRG1 signaling potentially contribute to the dis-
order phenotype.
To explore the consequence of increased NRG1 signaling on 
schizophrenia-relevant behavioral impairments, we adminis-
tered NRG1 to mice also receiving PCP. Consistent with previ-
ous publications, PCP treatment induced hyperlocomotion and 
impaired PPI (Bakshi and Geyer, 1995; Gleason and Shannon, 
1997; Mouri et al., 2011). We subsequently discovered that NRG1 
treatment dose-dependently prevented the PCP-induced hyper-
locomotion and PPI impairment (Figures 1 and 2B). The PCP-
rodent model is commonly used for identifying substances with 
antipsychotic-like potential (Adell et al., 2012). Current antipsy-
chotics, including olanzapine, clozapine, and haloperidol, have 
been shown to prevent PCP-induced hyperlocomotion and PPI 
impairments (Bakshi and Geyer, 1995; Gleason and Shannon, 
1997; Geyer et al., 2001; Linn et al., 2003; Mutlu et al., 2011). By 
preventing PCP-induced behavior impairments, NRG1 treatment 
shows antipsychotic-like potential. Remarkably, NRG1 i.c.v. and 
i.p. administrations had comparable outcomes against PCP-
induced hyperlocomotion, which suggests that peripheral NRG1 
administration has neuromodulatory properties on central 
receptors. This observation supports previous studies, which 
have shown that peripherally-administered recombinant NRG1 
can readily cross the blood-brain barrier (Kastin et al., 2004; Kato 
et al., 2011; Rösler et al., 2011).
NRG1 Reduces Glutamate and Glycine Levels and 
Prevents PCP-Induced GABA Increase In Vivo
In the brain, the NRG1 receptor ERBB4 is predominantly located 
on GABAergic interneurons, with high expression in the PFC and 
hippocampus (Fazzari et al., 2010; Neddens et al., 2011), which 
are associated with the behavioral symptoms of schizophrenia 
(Inan et  al., 2013). This expression pattern, together with the 
reported effects of NRG1 on neurotransmission in vitro, sug-
gests that NRG1 signaling may influence GABAergic and glu-
tamatergic neurotransmission in the PFC and hippocampus. 
We therefore assessed the effects of local NRG1 application on 
extracellular GABA, glutamate, and glycine levels in the PFC and 
hippocampus in vivo. Glutamate and glycine levels in both brain 
regions were reduced following NRG1 retrodialysis (Figure  3B 
and C and Figure 4B and C). This effect potentially contributes to 
the reported reduction in NMDA receptor currents and subunit 
internalization following NRG1 application in PFC slice prepara-
tions (Gu et al., 2005). While recent work shows that NRG1 can 
reduce glutamate release via the pre-synaptic LIMK1 protein 
(Yin et al., 2013), the exact mechanism underlying the present 
finding is worthy of further investigation.
NRG1 application in vitro has been shown to increase depo-
larization-evoked GABA release in the PFC by activating ERBB4 
receptors (Woo et  al., 2007; Wen et  al., 2010). Prolonged NRG1 
treatment has been shown to reduce surface levels of GABA-A 
receptors (Okada and Corfas, 2004), potentially compensat-
ing for the reported increase in GABA release. We observed an 
increase in GABA levels during the infusion period in the hip-
pocampus and, slightly delayed, in the PFC. Our in vivo findings 
suggest that GABA-releasing cells in the adult nervous system 
respond to acute NRG1 signaling, adding support to the existing 
in vitro studies.
Deficits in the GABAergic and glutamatergic system have 
been identified in the PFCs and hippocampi of patients with 
schizophrenia (Gonzalez-Burgos et  al., 2011; Nakazawa et  al., 
2012). We therefore investigated whether the response to NRG1 
administration would differ when combined with PCP. PCP treat-
ment caused a short-term increase in GABA levels in the hip-
pocampus. While reduced GABA levels in the PFCs of rodents 
following PCP infusion have been reported previously (Yonezawa 
et al., 1998; Zhu et al., 2004), these studies used higher PCP con-
centrations (10 vs 50 and 100  μM) coupled with longer treat-
ment durations (10 vs 40 min), which are likely responsible for 
the effect difference. Combined NRG1 and PCP infusion com-
pletely prevented the PCP-induced increase in GABA levels. The 
observed effect on GABA by combined NRG1 and PCP treatment 
occurred during the retrodialysis period, suggesting a direct 
action on local neurotransmitter release or uptake mechanisms. 
Notably, a recent study identified an interaction between ERBB4 
and GABA-A receptors in hippocampal interneurons, which 
possibly contributed to the observed NRG1 treatment effect 
(Mitchell et al., 2013).
In line with existing reports (Zhu et al., 2004), local PCP infu-
sion in the PFC and hippocampus did not change glutamate or 
glycine levels. However, glycine levels were markedly increased 
during the infusion period of NRG1 and PCP in both brain 
regions, while glutamate levels remained below baseline levels 
for the sampling period. Since the effect duration differs for both 
neurotransmitters, separate mechanisms are likely involved. 
Furthermore, there appears to be no correlation between the 
treatment effects on the extracellular levels of GABA, glutamate, 
and glycine. PCP and NRG1 have been reported to alter extracel-
lular dopamine levels in vivo (Yonezawa et al., 1998; Zhu et al., 
2004; Kwon et al., 2008). Assessing the effect of the combined 
treatment on dopamine levels will aid the understanding of 
mechanisms underlying the effect of NRG1 administration by 
itself and in the presence of PCP on neurotransmission.
The effect of antipsychotics on local PCP-induced neuro-
transmitter alterations has not been published. However, local 
clozapine and haloperidol administration have been reported 
to reduce GABA levels, with clozapine, but not haloperidol, also 
increasing glutamate levels in the PFCs of rats (Bourdelais and 
Deutch, 1994; López-Gil et  al., 2007). NRG1 infusion changed 
GABA, glutamate, and glycine levels in the presence of PCP, indi-
cating a potential for NRG1 signaling to acutely alter impaired 
neurotransmission.
The Potential Implications of Altered NRG1 Signaling 
in Schizophrenia
Existing in vitro experiments have indicated that NRG1 adminis-
tration is more likely to affect neurotransmitter receptor avail-
ability than neurotransmitter release in PFC and hippocampus 
slice preparations (Liu et al., 2001; Okada and Corfas, 2004; Chang 
and Fischbach, 2006; Pitcher et al., 2011; Shamir et al., 2012). The 
observed rapid neurotransmitter level changes following NRG1 
and the combined NRG1 and PCP infusion are therefore note-
worthy. However, since each sample covers a 10 min window, 
we cannot determine the exact order of neurochemical events, 
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which is of particular relevance since GABA and glycine have 
been reported to influence glutamate levels (Tanaka et al., 2003; 
Lee et al., 2009). Furthermore, the behavioral response to i.c.v. 
NRG1 suggests that neurotransmission in other brain regions, 
such as the striatum, are also rapidly affected.
The effects of NRG1-ERBB4 signaling have been suggested to 
follow an “inverted-U model” when studying neuronal activity 
(Role and Talmage, 2007). The dose-dependent response of NRG1 
against PCP-induced behavioral impairments indicates a non-
linear concentration response. U-shaped behavioral responses 
have been associated with PFC dopamine levels (Husain and 
Mehta, 2011), and are considered critical for the development 
of pharmacological agents targeting cognitive symptoms of 
schizophrenia (Millan et al., 2012). However, the bi-phasic dose-
response of NRG1 in the present study requires further explora-
tion using a wider concentration range to determine the exact 
NRG1-ERBB complex relationship. Broadening the concentration 
spectrum may also shed light on the consequence of altered 
NRG1 signaling in humans, since both increased and decreased 
NRG1 expression has been observed in patients with schizo-
phrenia (Deng et al., 2013). Furthermore, chronically increased 
or decreased NRG1 signaling in mice has led to behavioral and 
structural differences (Lu et al., 2011). This highlights the need 
to assess the NRG1 signaling system at different stages dur-
ing development. Such investigations will also provide critical 
information about the onset and duration of a possible NRG1 
treatment strategy following our identification of the antipsy-
chotic-like treatment potential. The suitability of NRG1 admin-
istration to humans has recently been explored in successful 
phase II clinical trials in patients with chronic heart failure (Gao 
et  al., 2010; Jabbour et  al., 2011). Thus, a combination of pre-
clinical and clinical data suggests that NRG1 has a therapeutic 
system-dependent effect, likely within a specific concentration 
range.
Conclusion
In the present study, we showed that acute treatment with 
NRG1 has little effect on spontaneous behavior, while signifi-
cantly reducing glutamatergic neurotransmission in the PFC 
and hippocampus. Importantly, our results demonstrate that 
NRG1 administration prevents schizophrenia-relevant behavior 
impairments and disruptions of the GABAergic system caused 
by PCP. The ability of NRG1 treatment to alter GABA, glutamate, 
and glycine levels in the presence of PCP also suggests that NRG1 
signaling has the potential to alter disrupted neurotransmission 
in patients with schizophrenia. Our findings are therefore the 
first step towards exploring the therapeutic potential of NRG1 
for the treatment of schizophrenia.
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